Masahiro Ono

Kyoto, 6068501, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 216 publications

Effect of Carbon-Chain Length in [125I]iodophenyl and [211At]astatophenyl Derivatives on Prostate-Specific Membrane Antigen-Targeted Radioligands.

Effect of Carbon-Chain Length in [125I]iodophenyl and [211At]astatophenyl Derivatives on Prostate-Specific Membrane Antigen-Targeted Radioligands.

Journal: Chemical & pharmaceutical bulletin

Published: September 02, 2026

Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding.

Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding.

Journal: Molecular pharmaceutics

Published: July 14, 2026

Bithiophene Scaffold for PET Imaging and Photosensitization as a Novel Theranostic Platform Targeting Amyloid-β Aggregates.

Bithiophene Scaffold for PET Imaging and Photosensitization as a Novel Theranostic Platform Targeting Amyloid-β Aggregates.

Journal: ACS chemical neuroscience

Published: June 30, 2026

Systematic Investigation of Fatty Acids with Different Carbon-Chain Length as Albumin Binder to Improve Tumor Accumulation of Radioligands.

Systematic Investigation of Fatty Acids with Different Carbon-Chain Length as Albumin Binder to Improve Tumor Accumulation of Radioligands.

Journal: Bioconjugate chemistry

Published: June 23, 2026

Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111In/177Lu Theranostics.

Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111In/177Lu Theranostics.

Journal: Bioconjugate chemistry

Published: June 12, 2026

Influence of the Binding Valency of Anti-HER2 Biparatopic Antibodies on Biodistribution in an SK-OV-3 Tumor Xenograft Model.

Influence of the Binding Valency of Anti-HER2 Biparatopic Antibodies on Biodistribution in an SK-OV-3 Tumor Xenograft Model.

Journal: Molecular pharmaceutics

Published: March 24, 2026

Head-to-Head Comparison of Monomeric, Homodimeric, and Heterodimeric Fibroblast Activation Protein-Targeting Radioligands Based on Small Molecule Inhibitor and Cyclic Peptide.

Head-to-Head Comparison of Monomeric, Homodimeric, and Heterodimeric Fibroblast Activation Protein-Targeting Radioligands Based on Small Molecule Inhibitor and Cyclic Peptide.

Journal: ACS pharmacology & translational science

Published: March 01, 2026

Dual pharmacokinetic modifier strategy for synergistically enhanced tumor accumulation of PSMA-targeting radioligand.

Dual pharmacokinetic modifier strategy for synergistically enhanced tumor accumulation of PSMA-targeting radioligand.

Journal: Chemical communications (Cambridge, England)

Published: February 16, 2026

Reply to the letter to the editor from Drs. Huang and Chen.

Reply to the letter to the editor from Drs. Huang and Chen.

Journal: Annals of nuclear medicine

Published: January 28, 2026

Preclinical evaluation of novel 177Lu-labeled fibroblast activation protein inhibitor with albumin binder for radioligand therapy.

Preclinical evaluation of novel 177Lu-labeled fibroblast activation protein inhibitor with albumin binder for radioligand therapy.

Journal: Annals of nuclear medicine

Published: November 10, 2025

A novel bivalent albumin binder for enhanced tumor retention of a fibroblast activation protein-targeted radioligand.

A novel bivalent albumin binder for enhanced tumor retention of a fibroblast activation protein-targeted radioligand.

Journal: Chemical communications (Cambridge, England)

Published: November 07, 2025

A new amyloid PET evaluation method using separated gray-matter histogram based on three-component model.

A new amyloid PET evaluation method using separated gray-matter histogram based on three-component model.

Journal: Annals of nuclear medicine

Published: November 06, 2025

Showing 1-12 of 216

Last Updated: 09/26/2026